- Home
- SNT vs THAR Comparison
SNT vs THAR Comparison
Compare SNT & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- THAR
- Stock Information
- Founded
- SNT 1965
- THAR 2017
- Country
- SNT Canada
- THAR United States
- Employees
- SNT N/A
- THAR N/A
- Industry
- SNT Telecommunications Equipment
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- THAR Health Care
- Exchange
- SNT Nasdaq
- THAR Nasdaq
- Market Cap
- SNT 95.2M
- THAR 101.7M
- IPO Year
- SNT 1993
- THAR 2022
- Fundamental
- Price
- SNT $4.65
- THAR $2.73
- Analyst Decision
- SNT
- THAR Strong Buy
- Analyst Count
- SNT 0
- THAR 1
- Target Price
- SNT N/A
- THAR $17.00
- AVG Volume (30 Days)
- SNT 52.8K
- THAR 3.4M
- Earning Date
- SNT 11-25-2025
- THAR 11-07-2025
- Dividend Yield
- SNT N/A
- THAR N/A
- EPS Growth
- SNT N/A
- THAR N/A
- EPS
- SNT 0.22
- THAR N/A
- Revenue
- SNT $38,038,000.00
- THAR N/A
- Revenue This Year
- SNT N/A
- THAR N/A
- Revenue Next Year
- SNT N/A
- THAR N/A
- P/E Ratio
- SNT $21.27
- THAR N/A
- Revenue Growth
- SNT 12.79
- THAR N/A
- 52 Week Low
- SNT $2.24
- THAR $0.95
- 52 Week High
- SNT $5.34
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- SNT 49.46
- THAR 41.26
- Support Level
- SNT $4.36
- THAR $2.82
- Resistance Level
- SNT $4.88
- THAR $5.27
- Average True Range (ATR)
- SNT 0.27
- THAR 0.75
- MACD
- SNT -0.02
- THAR -0.08
- Stochastic Oscillator
- SNT 51.83
- THAR 0.48
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.